1-10 of 10
Zheng Yan
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Preliminary Safety and Biomarker Results of the NLRP3 Inflammasome Inhibitor DFV890 in Adult Patients with Myeloid Diseases: A Phase 1b Study

Guillermo Garcia-Manero, Yasmin Abaza, Peter L. Greenberg, Tamanna Haque, Kyra Velázquez Kennedy, Matteo Giovanni Della Porta, Melissa G Ooi, Maximilian Stahl, Zhuoer Xie, Abhishek A. Mangaonkar, Pinkal Desai, Amy E. DeZern, Alice Garnier, Mathieu Meunier, Anna Maria Pelizzari, Uwe Platzbecker, Katja Sockel, Ashwin Kishtagari, Hongbo Lu, Luca Manganelli, Lexiang Ji, Zheng Yan, Yutong Li, Mike Roy, Ewa Gatlik, Arti Singh, Valerie Beaulieu, Marc Pelletier, Philipp Rauch, Harinder Gill
Journal: Blood
Blood (2024) 144 (Supplement 1): 353.
https://doi.org/10.1182/blood-2024-198326
Published: 2024
Journal Articles

Preliminary Results of a Phase Ⅱ Study of Lenalidomide Combined with Immunochemotherapy in Patients with Primary Central Nervous System Lymphoma

Shuna Yao, Zhihua Yao, Zheng Yan, Haiying Wang, Junfeng Chu, Shuang Zhao, Xinyang Zhao, Yanyan Liu
Journal: Blood
Blood (2023) 142 (Supplement 1): 1758.
https://doi.org/10.1182/blood-2023-189345
Published: 2023
Journal Articles

Phase II Clinical Trial of R-CHOP Combined with Lenalidomide in the First-Line Treatment for Patients with High Risk Diffuse Large B Cell Lymphoma

Shuang Zhao, Jiuyang Zhang, Zheng Yan, Yuanlin Xu, Zhihua Yao, Junfeng Chu, Shuna Yao, Haiying Wang, Wenping Zhou, Xufeng Luo, Peipei Zhang, Yanyan Liu
Journal: Blood
Blood (2023) 142 (Supplement 1): 6237.
https://doi.org/10.1182/blood-2023-185955
Published: 2023
Journal Articles

Selective PI3Kδ Inhibitor Parsaclisib Combined with HDAC Inhibitor Chidamide in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma: Preliminary Results of a Phase Ib/Ⅱ Study

Zheng Yan, Shuna Yao, Shuang Zhao, Haiying Wang, Junfeng Chu, Yuanlin Xu, Jiuyang Zhang, Lina Zhang, Quande Lin, Lijie Liang, Ping Wang, Wenyong Li, Xiaolu Teng, Zhihua Yao, Yanyan Liu
Journal: Blood
Blood (2023) 142 (Supplement 1): 3075.
https://doi.org/10.1182/blood-2023-185902
Published: 2023
Journal Articles

Phase II Clinical Trial of Camrelizumab Combined with AVD (Epirubicin, Vincristine and Dacarbazine) in the First-Line Treatment for Patients with Advanced Classical Hodgkin's Lymphoma

Shuang Zhao, Yanyan Liu, Zhihua Yao, Zheng Yan, Shuna Yao, Junfeng Chu, Haiying Wang, Jiuyang Zhang, Peipei Zhang, Wenping Zhou
Journal: Blood
Blood (2022) 140 (Supplement 1): 6579–6580.
https://doi.org/10.1182/blood-2022-166829
Published: 2022
Journal Articles

Preliminary Results of a Phase Ⅱ Study of Zanubrutinib Combined with Immunochemotherapy in Patients with CD79A/CD79B-Mutant Diffuse Large B-Cell Lymphoma

Zhihua Yao, Zheng Yan, Shuna Yao, Haiying Wang, Junfeng Chu, Shuang Zhao, Jie Ma, Bing Wei, Jiawen Zheng, Quande Lin, Zheng Xu, Xinyang Zhao, Yanyan Liu
Journal: Blood
Blood (2022) 140 (Supplement 1): 3767–3768.
https://doi.org/10.1182/blood-2022-165944
Published: 2022
Journal Articles

Preclinical Development of an Anti-CD38 Antibody-Drug Conjugate for Treatment of Hematological Malignancies

Lingna Li, PhD, Wenyong Tong, PhD, Megan Lau, BS, Katherine Fells, PhD, Tong Zhu, PhD, Yingqing Sun, PhD, Ernest Kovacs, PhD, Alisher Khasanov, PhD, Zheng Yan, PhD, Dalun Deng, PhD, Ken Takeshita, MD, Gunnar F. Kaufmann, PhD, Henry Ji, PhD, Hui Li, PhD, Hong Zhang, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5621.
https://doi.org/10.1182/blood-2019-132062
Published: 2019
Journal Articles

Preclinical Development of a Bcma Targeting Antibody-Drug Conjugate with Novel Payload for Multiple Myeloma Therapy

Andrew Hau, PhD, Tong Zhu, PhD, Rengang Wang, PhD, Megan Lau, BS, Lingna Li, PhD, Xiaoqing Li, PhD, Yingqing Sun, PhD, Ernest Kovacs, PhD, Alisher Khasanov, PhD, Dalun Deng, PhD, Zheng Yan, PhD, Robert D. Knight, MD, Gunnar F. Kaufmann, PhD, Henry Ji, PhD, Hui Li, PhD, Hong Zhang, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5623.
https://doi.org/10.1182/blood-2019-132080
Published: 2019
Journal Articles

Clinical Outcome of P-Gemox ( Pegaspargase, Gemcitabine, Oxaliplatin ) for the Patients with Newly Diagnosed Stage III/IV or Relapsed/Refractory Extranodal Natural Killer/T Cell Lymphoma

Huiqiang Huang, MD, Yan Gao, XiaoXiao Wang, Qingqing Cai, MD, QiChun Cai, Bing Bai, Wei Zhao, Zheng Yan, Wenqi Jiang, MD PhD, Zhongjun Xia, MD, ZhiMing Li
Journal: Blood
Blood (2015) 126 (23): 1521.
https://doi.org/10.1182/blood.V126.23.1521.1521
Published: 2015
Journal Articles

Longterm Outcome of Induction Chemotherapy of P-Gemox Regimen Followed By Extensive Involved-Field Radiotherapy(EIFRT) for Newly Diagnosed Stage I/II Extranodal Natural Killer/T-Cell Lymphoma---a Single Center Experience

Huiqiang Huang, MD, Yan Gao, XiaoXiao Wang, Qingqing Cai, MD, QiChun Cai, Bing Bai, Zheng Yan, Wenqi Jiang, Zhongjun Xia, MD, ZhiMing Li
Journal: Blood
Blood (2015) 126 (23): 3936.
https://doi.org/10.1182/blood.V126.23.3936.3936
Published: 2015